Buprenorphine Drug Asset Due Diligence Report 2026

This Buprenorphine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

249

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Buprenorphine can convert its Small molecule drug profile and κ opioid receptor x μ opioid receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Buprenorphine (query alias: buprenorphine)
Modality / target	Small molecule drug; κ opioid receptor x μ opioid receptor; κ opioid receptor agonists, μ opioid receptor antagonists
Highest global status	Approved
Originator	OrphoMed, Inc.
Active developers	Indivior Pty Ltd., Indivior, Inc., Nutriband, Inc.

The MCP disease footprint includes Opioid-Related Disorders, Opium Dependence, Opioid abuse. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07176351	Phase 4	Not yet recruiting	60	Retention of XR-B at month 6
ACTRN12625000385448	Phase 2	Recruiting	18	Not disclosed
CTR20254642	Not Applicable	进行中（招募完成）	16	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): a Pragmatic Randomized Trial Comparing Extended-release and Daily Buprenorphine Formulations

Phase 3; n=140; evaluation: not stated. Reported fields: Percentage of Illicit Opioid-negative Urine Samples During Pregnancy(Mean) = 82.5 % Illicit opioid-negative urine samples (Standard Error, 4.2); -; -

Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum

Phase 3; n=140; evaluation: Positive. Reported fields: Illicit opioid abstinence(during pregnancy) = 72.6 % ; Illicit opioid abstinence(during pregnancy) = 82.5 %

Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections

Phase 2; n=71; evaluation: not stated. Reported fields: -; Illicit Opioid Use = 0.434 Proportion of UDS samples ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Buprenorphine addresses Opioid-Related Disorders, Opium Dependence, Opioid abuse. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-12-10	Virginia Tech collaborates with Indivior to investigate long-term recovery in individuals with opioid use disorder.	Not disclosed	Financial terms not disclosed
2018-09-04	TITAN AND THE NEVADA CENTER FOR BEHAVIORAL HEALTH COLLABORATE TO EVALUATE PROBUPHINE® TREAMENT OF OUD PATIENTS WITHIN THE STATE OF NEVADA CRIMINAL JUSTICE SYSTEM	Approved	Financial terms not disclosed
2014-11-20	Camurus and Braeburn Pharmaceuticals sign exclusive license for long-acting buprenorphine injectables for the treatment of opioid dependence and pain	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Injectable sustained release buprenorphine formulation”. The milestone feed surfaced a patent-application signal described as “Buprenorphine implant and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Stable formulations of buprenorphine”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO